Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

Jørgensen, Heather G and Allan, Elaine K and Mountford, Joanne C and Richmond, Linda and Harrison, Simon and Elliott, Moira A and Holyoake, Tessa L (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33 (10). pp. 1140-6. ISSN 0301-472X

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.

Item type: Article
ID code: 32632
Keywords: antigens, antineoplastic agents, apoptosis, bryostatins, drug antagonism, hematopoietic stem cells, leukemia, macrolides, piperazines, protein kinase C, pyrimidines, Therapeutics. Pharmacology, Neoplasms. Tumors. Oncology (including Cancer)
Subjects: Medicine > Therapeutics. Pharmacology
Medicine > Internal medicine > Neoplasms. Tumors. Oncology (including Cancer)
Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Related URLs:
    Depositing user: Pure Administrator
    Date Deposited: 19 Aug 2011 21:05
    Last modified: 17 Jul 2013 10:45
    URI: http://strathprints.strath.ac.uk/id/eprint/32632

    Actions (login required)

    View Item